Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology & Drugs -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (113)	7/15/2002 7:31:49 AM
From: SusieQ1065	Read Replies (1) \| Respond to of 232

07:26 ET Amgen to attack J&J over anaemia drug Eprex-- FT The Financial Times reports that AMGN is expected today to launch an attack on the safety of JNJ's anaemia drug Eprex; the article states that AMGN's move is an attempt to distance itself from side effects linked to Eprex, which is made by JNJ and licenced from AMGN; AMGN fears that the problem could threaten its two biggest selling products, Epogen and Aranesp, which are almost identical to Eprex and accounted for more than half its $4 bln revenues in 2001.